Literature DB >> 12519404

Increased expression of the secretory leukocyte proteinase inhibitor in Wegener's granulomatosis.

S Ohlsson1, R Falk, J J Yang, K Ohlsson, M Segelmark, J Wieslander.   

Abstract

The secretory leucocyte proteinase inhibitor (SLPI) is a low molecular weight, tissue-specific inhibitor of proteases, such as elastase and cathepsin G. It is the major local protease inhibitor in the upper airways. Proteinase 3, the main autoantigen in Wegener's granulomatosis (WG), can degrade SLPI proteolytically. In addition, SLPI is sensitive to oxidative inactivation by myeloperoxidase-generated free oxygen radicals. SLPI also has an antimicrobial capacity that can be of interest, as infection is considered to play a role in the pathogenesis of WG. This study focuses on SLPI expression in patients suffering from WG, something that to our knowledge has not been explored hitherto. Serum samples and nasal biopsies were obtained from 12 Swedish WG patients, while buffy coats were obtained from 33 American WG patients. SLPI levels in serum were measured by means of ELISA and the protein was detected by means of immunohistochemistry in nasal biopsies. mRNA expression was studied by means of in situ hybridization on nasal biopsies and RT-PCR on leucocytes. IL-6 or ESR were measured as markers of inflammatory activity. Cystatin C or creatinine was measured as a marker of renal filtration. White blood cell counts were registered. In serum, we found close to normal SLPI levels, without any correlation to IL-6. Two patients had greatly elevated values, both of them suffering from severe renal engagement. Strong SLPI mRNA expression was found in nasal biopsies. RT-PCR on leucocyte mRNA showed normal or greatly elevated expression of SLPI mRNA, correlating with disease activity. Leukocyte SLPI expression seems to be up-regulated in active WG. Serum levels were measured in a small number of patients and were found to be close to normal. Lack of correlation to the acute phase response indicates a specific regulation. This might be linked to an altered protease/antiprotease balance. These findings could indicate that SLPI locally participates in the anti-inflammatory and perhaps antimicrobial response in WG.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519404      PMCID: PMC1808594          DOI: 10.1046/j.1365-2249.2003.02024.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

Review 1.  Proteinase-activated receptors.

Authors:  S R Macfarlane; M J Seatter; T Kanke; G D Hunter; R Plevin
Journal:  Pharmacol Rev       Date:  2001-06       Impact factor: 25.468

2.  Secretory leukocyte protease inhibitor in normal, allergic and virus induced nasal secretions.

Authors:  U Fryksmark; M Jannert; K Ohlsson; H Tegner; J A Wihl
Journal:  Rhinology       Date:  1989-06       Impact factor: 3.681

3.  Studies on the role of antileukoprotease in respiratory tract diseases.

Authors:  U Fryksmark; T Prellner; H Tegner; K Ohlsson
Journal:  Eur J Respir Dis       Date:  1984-04

4.  ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells.

Authors:  W F Pendergraft; D A Alcorta; M Segelmark; J J Yang; R Tuttle; J C Jennette; R J Falk; G A Preston
Journal:  Kidney Int       Date:  2000-05       Impact factor: 10.612

5.  Increased concentrations of secretory leukocyte protease inhibitor in peritoneal fluid of women with endometriosis.

Authors:  K Shimoya; A Moriyama; I Ogata; T Nobunaga; M Koyama; C Azuma; Y Murata
Journal:  Mol Hum Reprod       Date:  2000-09       Impact factor: 4.025

6.  Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-beta (TGF-beta), by lipopolysaccharide-stimulated macrophages.

Authors:  C Sano; T Shimizu; K Sato; H Kawauchi; H Tomioka
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

7.  Alpha 1-proteinase inhibitor and mucus proteinase inhibitor in human lung emphysema.

Authors:  G Trefz; J Schliesser; B Heck; V Schulz; W Ebert
Journal:  Clin Investig       Date:  1992 Mar-Apr

8.  Influence of elastin on the inhibition of leucocyte elastase by alpha 1-proteinase inhibitor and bronchial inhibitor. Potent inhibition of elastin-bound elastase by bronchial inhibitor.

Authors:  M Bruch; J G Bieth
Journal:  Biochem J       Date:  1986-08-15       Impact factor: 3.857

9.  Novel distribution of the secretory leucocyte proteinase inhibitor in kidney.

Authors:  S Ohlsson; I Ljungkrantz; K Ohlsson; M Segelmark; J Wieslander
Journal:  Mediators Inflamm       Date:  2001-12       Impact factor: 4.711

10.  Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.

Authors:  M Nyström; M Bergenfeldt; I Ljungcrantz; A Lindeheim; K Ohlsson
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

View more
  3 in total

1.  The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.

Authors:  Gheath Alatrash; Yoko Ono; Anna Sergeeva; Pariya Sukhumalchandra; Mao Zhang; Lisa S St John; Tian-Hui Yang; Kathryn Ruisaard; Paul M Armistead; Elizabeth A Mittendorf; Hong He; Na Qiao; Tania Rodriguez-Cruz; Shoudan Liang; Karen Clise-Dwyer; Eric D Wieder; Gregory Lizee; Sijie Lu; Jeffrey J Molldrem
Journal:  J Immunother       Date:  2012-05       Impact factor: 4.456

2.  Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression.

Authors:  Thomas Wex; Doerthe Kuester; Cornelius Schönberg; Daniel Schindele; Gerhard Treiber; Peter Malfertheiner
Journal:  BMC Gastroenterol       Date:  2011-05-26       Impact factor: 3.067

Review 3.  Molecular Mechanisms Involved in Intrarenal Renin-Angiotensin and Alternative Pathways in Diabetic Nephropathy - A Review.

Authors:  Elham Bahreini; Yousef Rezaei-Chianeh; Mohsen Nabi-Afjadi
Journal:  Rev Diabet Stud       Date:  2021-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.